drugset / Trial / NCT05358938
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
Timeline
- Start
- 2022-06-21
- Primary completion
- 2024-10-06
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Avelumab | Monoclonal antibody | — | — |
| Background | Cemiplimab | Monoclonal antibody | — | — |
| Background | Ipilimumab | Monoclonal antibody | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |